Hydrocortisone normalizes phosphodiesterase-5 activity in pulmonary artery smooth muscle cells from lambs with persistent pulmonary hypertension of the newborn

Pulmonary Circulation

Volumn 4, Issue 1, 2014, Pages 71-81

  Perez, Marta ^a   Wedgwood, Stephen ^b   Lakshminrusimha, Satyan ^c   Farrow, Kathryn N ^a   Steinhorn, Robin H ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Hydrocortisone; NF B; Oxidative stress; PDE5; PPHN

Indexed keywords

EID: 85026337791     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/674903     Document Type: Article

References (52)

1. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000; 105:14-20.
2. Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am 2009;56:579-600.
3. Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med 2010;11:S79-S84.
4. Lakshminrusimha S. The pulmonary circulation in neonatal respiratory failure. Clin Perinatol 2012;39:655-683.
5. Steinhorn RH. Therapeutic approaches using nitric oxide in infants and children. Free Rad Biol Med 2011;51:1027-1034.
6. Steinhorn RH. Pharmacotherapy for pulmonary hypertension. Pediatr Clin North Am 2012;59:1129-1146.
7. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. New Engl J Med 2000;342:469-474.
8. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. New Engl J Med 1997;336:597-604.
9. Lakshminrusimha S, Russell JA, Steinhorn RH, et al. Pulmonary arterial contractility in neonatal lambs increases with 100% oxygen resuscitation. Pediatr Res 2006;59:137-141.
10. Vento M, Saugstad OD. Oxygen supplementation in the delivery room: updated information. J Pediatr 2011;158: e5-e7.
11. Lakshminrusimha S, Steinhorn RH, Wedgwood S, et al. Pulmonary hemodynamics and vascular reactivity in asphyxiated term lambs resuscitated with 21 and 100% oxygen. J Appl Physiol 2011;111:1441-1447.
12. Farrow KN, Steinhorn RH. Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension. Handb Exp Pharmacol 2011:251-277.
13. Farrow KN, Groh BS, Schumacker PT, et al. Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ Res 2008; 102:226-233.
14. Farrow KN, Lakshminrusimha S, Czech L, et al. SOD and inhaled nitric oxide normalize phosphodiesterase 5 expression and activity in neonatal lambs with persistent pulmonary hypertension. Am J Physiol Lung Cell Mole Physiol 2010;299:L109-L116.
15. Lakshminrusimha S, Swartz DD, Gugino SF, et al. Oxygen concentration and pulmonary hemodynamics in newborn lambs with pulmonary hypertension. Pediatr Res 2009;66: 539-544.
16. Farrow KN, Wedgwood S, Lee KJ, et al. Mitochondrial oxidant stress increases PDE5 activity in persistent pulmonary hypertension of the newborn. Respir Physiol Neurobiol 2010; 174:272-281.
17. Michiels C, Minet E, Mottet D, Raes M. Regulation of gene expression by oxygen: NF-kappaB and HIF-1, two extremes. Free Rad Biol Med 2002;33:1231-1242.
18. Wright CJ, Zhuang T, La P, Yang G, Dennery PA. Hyperoxiainduced NF-kappaB activation occurs via a maturationally sensitive atypical pathway. Am J Physiol Lung Cell Mol Physiol 2009;296:L296-L306.
19. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991;10:2247-2258.
20. Amore A, Formica M, Giacchino F, et al. N-acetylcysteine in hemodialysis diabetic patients resets the activation of NF-kB in lymphomonocytes to normal values. J Nephrol 2013;26:778-786.
21. Blackwell TS, Blackwell TR, Holden EP, Christman BW, Christman JW. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol 1996;157:1630-1637.
22. Liu ZQ, Liu B, Yu L, Wang XQ, Wang J, Liu HM. Simvastatin has beneficial effect on pulmonary artery hypertension by inhibiting NF-kappaB expression. Mol Cell Biochem 2011;354:77-82.
23. Bourbia A, Cruz MA, Rozycki HJ. NF-kappaB in tracheal lavage fluid from intubated premature infants: association with inflammation, oxygen, and outcome. Arch Dis Child Fetal Neonatal Ed 2006;91:F36-F39.
24. Wedgwood S, Lakshminrusimha S, Czech L, Schumacker PT, Steinhorn RH. Increased p22phox/Nox4 expression is involved in remodeling through hydrogen peroxide signaling in experimental persistent pulmonary hypertension of the newborn. Antioxid Redox Signal 2013;18:1765-1776.
25. Soukka H, Halkola L, Aho H, Rautanen M, Kero P, Kaapa P. Methylprednisolone attenuates the pulmonary hypertensive response in porcin meconium aspiration. Pediatr Res 1997;42:145-150.
26. Basu S, Kumar A, Bhatia BD, Satya K, Singh TB. Role of steroids on the clinical course and outcome of meconium aspiration syndrome-a randomized controlled trial. J Trop Pediatr 2007;53:331-337.
27. Tripathi S, Saili A. The effect of steroids on the clinical course and outcome of neonates with meconium aspiration syndrome. J Trop Pediatr 2007;53:8-12.
28. Ward M, Sinn J. Steroid therapy for meconium aspiration syndrome in newborn infants. Cochrane Database Syst Rev 2003:CD003485.
29. Chandrasekar I, Eis A, Konduri GG. Betamethasone attenuates oxidant stress in endothelial cells from fetal lambs with persistent pulmonary hypertension. Pediatr Res 2008; 63:67-72.
30. Perez M, Lakshminrusimha S, Wedgwood S, et al. Hydrocortisone normalizes oxygenation and cGMP regulation in lambs with persistent pulmonary hypertension of the newborn. Am J Physiol Lung Cell Mol Physiol 2012;302:L595-L603.
31. Almawi WY, Melemedjian OK. Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids. J Mol Endocrinol 2002;28:69-78.
32. Pyne NJ, Murray F, Tate R, MacLean MR. Molecular determinants in pulmonary hypertension: the role of PDE5. In: Beavo JA, Francis SH, Houslay MD, eds. Cyclic Nucleotide Phosphodiesterases in Health and Disease. Boca Raton, FL: CRC/Taylor & Francis, 2007:510-511.
33. Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics 1995;95:120-125.
34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72: 248-254.
35. Hanson GT, Aggeler R, Oglesbee D, et al. Investigating mitochondrial redox potential with redox-sensitive green fluorescent protein indicators. J Biol Chem 2004;279:13044-13053.
36. Waypa GB, Marks JD, Guzy R, et al. Hypoxia triggers subcellular compartmental redox signaling in vascular smooth muscle cells. Circ Res 2010;106:526-535.
37. Wedgwood S, Lakshminrusimha S, Fukai T, Russell JA, Schumacker PT, Steinhorn RH. Hydrogen peroxide regulates extracellular superoxide dismutase activity and expression in neonatal pulmonary hypertension. Antioxid Redox Signal 2011;15:1497-1506.
38. Carnesecchi S, Deffert C, Pagano A, et al. NADPH oxidase-1 plays a crucial role in hyperoxia-induced acute lung injury in mice. Am J Respir Crit Care Med 2009;180:972-981.
39. Yoshioka T, Kawamura T, Meyrick BO, et al. Induction of manganese superoxide dismutase by glucocorticoids in glomerular cells. Kidney Int 1994;45:211-219.
40. Kinnula VL, Crapo JD. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med 2003;167:1600-1619.
41. Sawada H, Mitani Y, Maruyama J, et al. A nuclear factorkappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest 2007;132:1265-1274.
42. Wright CJ, Agboke F, Chen F, La P, Yang G, Dennery PA. NO inhibits hyperoxia-induced NF-kappaB activation in neonatal pulmonary microvascular endothelial cells. Pediatr Res 2010;68:484-489.
43. Folz RJ, Abushamaa AM, Suliman HB. Extracellular superoxide dismutase in the airways of transgenic mice reduces inflammation and attenuates lung toxicity following hyperoxia. J Clin Invest 1999;103:1055-1066.
44. Schreck R, Albermann K, Baeuerle PA. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 1992;17: 221-237.
45. Iwasaki T, Takahashi T, Shimizu H, et al. Increased pulmonary heme oxygenase-1 and delta-aminolevulinate synthase expression in monocrotaline-induced pulmonary hypertension. Curr Neurovasc Res 2005;2:133-139.
46. Aghai ZH, Kode A, Saslow JG, et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesisof pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res 2007;62:483-488.
47. Aghai ZH, Kumar S, Farhath S, et al. Dexamethasone suppresses expression of nuclear factor-kappaB in the cells of tracheobronchial lavage fluid in premature neonates with respiratory distress. Pediatr Res 2006;59:811-815.
48. Suzuki Y, Nishio K, Takeshita K, et al. Effect of steroid on hyperoxia-induced ICAM-1 expression in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 2000;278: L245-L252.
49. Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 2002;137:1187-1194.
50. Ahmed MN, Codipilly C, Hogg N, Auten RL. The protective effect of overexpression of extracellular superoxide dismutase on nitric oxide bioavailability in the lung after exposure to hyperoxia stress. Exp Lung Res 2011;37: 10-17.
51. Savai R, Pullamsetti SS, Kolbe J, et al. Immune/inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:897-908.
52. de Visser YP, Walther FJ, Laghmani El H, Boersma H, van der Laarse A, Wagenaar GT. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir Res 2009;10:30.